Skip to main content
Figure 2 | Retrovirology

Figure 2

From: Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein

Figure 2

Triptolide potently inhibits HIV-1 replication in vitro . (A) The effect of triptolide on HIV-1 replication in TZM-bl reporter cells. TZM-bl cells were infected with HIV-1 (MOI = 0.5, strain NL4-3) in the presence of 3-fold serial dilutions of triptolide. Virus replication was quantified by measuring luciferase expression at 48 h post-infection. A cell viability assay was carried out in parallel using CellTiter-Glo. (B) The effect of triptolide on HIV-1 reporter virus replication in Jurkat cells. Jurkat cells were infected with HIV-1-Luc (pNL4-3.Luc.R-E- pseudotyped with the NL4-3 envelope) at an MOI of 0.5 in the presence of triptolide. Luciferase gene expression was quantified at 48 h post-infection. Compound cytotoxicity was determined in mock-infected cells. (C) Cytotoxicity of triptolide in PBMCs. PBMCs from donor A were treated with the indicated concentrations of triptolide for six days before cell viability examination using CellTiter-Glo. (D) Inhibition of HIV-1 replication in PBMCs. PBMCs from donor A were infected with HIV-1 (MOI = 0.01, strain NL4-3) in the presence of increasing concentrations of triptolide. Supernatants were collected at the indicated days post-infection and virus replication levels were determined using p24 ELISA. Results were presented as the mean plus the standard deviations (n = 3).

Back to article page